Studies by Ashton et al. [78] and Smirnov et al. [116] supported the finding that p-tau231 is the first p-tau marker to reach abnormal levels within the pre-Aβ phase, making it a valuable tool for the early detection of AD pathology. Here, MAPT is linked to Alzheimer disease.